

# Eliminating TB as a public health problem

## THE TB CHALLENGE

With 1.5 million people dying and 10 million affected each year worldwide, tuberculosis (TB) is a leading cause of death and suffering from an infectious disease.

Consequently, new drugs and shorter regimens for the treatment of TB, and their rapid uptake, are urgently needed if we are to reach the ambitious targets of 95% death reduction and 90% incidence decline by 2035 set by the World Health Organization in its End TB global strategy.

## UNITE4TB


With 30 partners from 13 countries, UNITE4TB aims to accelerate and improve the clinical evaluation of novel compounds and drug combinations to develop new and effective anti-TB treatments for drug-resistant and drug-sensitive TB.

Our vision is to be the start of a major enterprise, in collaboration with centres of excellence around the world, that ensures there is sustained investment in TB drug development in the years to come so that the elimination of TB as a public health problem is finally achieved.



UNITE4TB aims to deliver more effective and shorter regimens through innovative clinical trial designs that conform to the highest regulatory standards.


Martin Boeree  
UNITE4TB Project Lead, Radboudumc



It's encouraging to see this promising innovative initiative that could make the world of difference for people affected by TB who struggle to get the right medications in the right combinations at the right price. UNITE4TB gives people affected by TB hope!


Blessina Kumar, UNITE4TB Community Advisory Group member

## Project dashboard



UNITE4TB will be active in four WHO regions (Europe, Asia, Africa and South America), with the goal of delivering novel phase 2 clinical trials that will accelerate the development of new anti-TB drugs and regimens.

## treatment regimens visualised as race-cars




- input**
- in vitro studies
  - animal studies
  - hollow fibre
  - phase 1



**trial & analysis**  
feeding/improve

## Product results

- new regimen(s) phase 3 ready
- improved TB trial design
- knowledge on TB treatment and geographic dependencies
- international network of TB experts and patient advocates
- FAIR data for further analyses



**regimen optimisation**  
selection of compound combinations + dose adjusting microbiology + biomarkers (phase 2A)

**intelligent design**  
study design + pharmacology + microbiology + biomarkers

**self-learning system**  
artificial intelligence

**intermediate checks**  
treatments (cars) re-adjusted at the pitstop



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.



Scan this QR code with the camera of your smartphone for more info

